Current Treatment Options in Oncology最新文献_第2页

Management Approaches for High-Risk Cutaneous Squamous Cell Carcinoma with Perineural Invasion: An Updated Review. 高风险皮肤鳞状细胞癌伴有神经周围侵犯的处理方法：最新综述。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-09-01 Epub Date: 2024-08-05 DOI: 10.1007/s11864-024-01234-z

Martina Catalano, Filippo Nozzoli, Francesco De Logu, Romina Nassini, Giandomenico Roviello

{"title":"Management Approaches for High-Risk Cutaneous Squamous Cell Carcinoma with Perineural Invasion: An Updated Review.","authors":"Martina Catalano, Filippo Nozzoli, Francesco De Logu, Romina Nassini, Giandomenico Roviello","doi":"10.1007/s11864-024-01234-z","DOIUrl":"10.1007/s11864-024-01234-z","url":null,"abstract":"Opinion statement: Cutaneous squamous cell carcinoma (cSCC) stands as the second most prevalent non-melanoma skin cancer worldwide, comprising approximately 20% of all cutaneous malignancies. Determining its precise incidence poses challenges; however, reports indicate a global increase in its prevalence. At the time of diagnosis, the majority of cSCCs are localized, resulting in favorable 5-year cure rates surpassing 90%. Nevertheless, a subset of patients (3-7%) encounters locally advanced or metastatic cSCC, leading to substantial morbidity and mortality. The risk of metastasis ranges from 0.1% to 9.9%, carrying an associated mortality risk of 2.8%. Factors influencing recurrence, metastasis, and disease-specific mortality underscore the significance of perineural invasion (PNI) as a key indicator. Patients with PNI may manifest clinical symptoms and/or radiologic signs of PNI, while the majority remain asymptomatic, and PNI is frequently identified upon histologic examination. Despite its lower frequency compared to other cancer types, PNI serves as a recognized adverse prognostic factor for cSCC. Surgery is the elective treatment for these patients, while the role of adjuvant radiotherapy (ART) is yet contentious and have not been conclusively assessed, particularly in clear surgical margin. Prospective comparative studies are required to comprehensively evaluate the benefit and the risks of ART for cSCC and PNI patients.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11416415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141890756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modern Management of Gastric Neuroendocrine Neoplasms. 胃神经内分泌肿瘤的现代治疗。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-09-01 Epub Date: 2024-07-31 DOI: 10.1007/s11864-024-01207-2

John W Kunstman, Anil Nagar, Joanna Gibson, Pamela L Kunz

{"title":"Modern Management of Gastric Neuroendocrine Neoplasms.","authors":"John W Kunstman, Anil Nagar, Joanna Gibson, Pamela L Kunz","doi":"10.1007/s11864-024-01207-2","DOIUrl":"10.1007/s11864-024-01207-2","url":null,"abstract":"Opinion statement: Gastric neuroendocrine neoplasms (G-NENs) are a heterogeneous group of tumors that broadly fall into two groups. The first group, driven by oversecretion of gastrin, are generally multifocal, small, and behave indolently with a low (but non-zero) risk of progression and metastatic spread. They are conventionally categorized into type 1, with endogenous gastric-based overproduction of gastrin, and type 2 G-NEN, with overproduction of gastrin from an extra-gastric gastrin-secreting tumor. The second group, termed type 3 G-NEN, occur spontaneously and are potentially more aggressive, having a clinical course analogous to other neuroendocrine tumors of the gastrointestinal tract. Type 1 G-NEN can be managed with endoscopic surveillance and resection of visible lesions with great success, reserving surgery for the rare high-risk lesion, whereas surgical resection of the causative gastrin-secreting tumor in type 2 G-NEN is usually curative. Type 3 G-NEN is usually managed with formal surgical resection but there is growing evidence that limited surgery or even endoscopic resection in appropriately selected patients with low risk is both safe and effective. A novel subtype of G-NEN, associated with long-term proton pump inhibitor usage, is increasing in incidence. The pathophysiology seems to parallel type 1 G-NEN. In the setting of metastatic disease, which can occur in any subtype but is most common by far in type 3 G-NEN, the lack of trial data unique to G-NEN results in extrapolation of strategies and agents for treatment of non-gastric neuroendocrine disease. The rapid pace of development in this area is likely to benefit the metastatic G-NEN patient as well. As treatment is predicate on type of G-NEN, establishing the etiology of the lesion is crucial but growing knowledge of G-NEN pathophysiology and close collaboration between pathologists, gastroenterologists, radiologists, surgeons, and oncologists have enabled a growing trend towards de-escalation and less-invasive treatment paradigms.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141856979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neuropathic Pain in Cancer: What Are the Current Guidelines? 癌症患者的神经性疼痛：当前的指导方针是什么？

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-09-01 Epub Date: 2024-08-05 DOI: 10.1007/s11864-024-01248-7

Matthew R Mulvey, Carole A Paley, Anna Schuberth, Natalie King, Andy Page, Karen Neoh

引用次数: 0

Gastrointestinal Cancer Therapy and Cardiotoxicity. 胃肠道癌症治疗与心脏毒性

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-09-01 Epub Date: 2024-08-05 DOI: 10.1007/s11864-024-01236-x

Orly Leiva, Talal El Zarif, Jose Alvarez-Cardona

引用次数: 0

Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer. 新辅助治疗：ER阳性/HER2阴性和三阴性早期乳腺癌的现状与未来展望》。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-09-01 Epub Date: 2024-08-15 DOI: 10.1007/s11864-024-01251-y

Hervé Bischoff, Marc Espié, Thierry Petit

{"title":"Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer.","authors":"Hervé Bischoff, Marc Espié, Thierry Petit","doi":"10.1007/s11864-024-01251-y","DOIUrl":"10.1007/s11864-024-01251-y","url":null,"abstract":"Opinion statement: Navigating the complex landscape of breast cancer treatment involves distinct strategies for luminal and triple-negative subtypes. While neoadjuvant chemotherapy historically dominates the approach for aggressive triple-negative tumors, recent evidence highlights the transformative impact of immunotherapy, alongside chemotherapy, in reshaping treatment paradigms. In luminal cancers, endocrine therapy, notably aromatase inhibitors, demonstrates promising outcomes in postmenopausal patients with low-grade luminal A tumors. However, integrating targeted therapies like CDK4/6 inhibitors in neoadjuvant setting remains inconclusive. Identifying predictive factors for treatment response, especially in luminal tumors, poses a challenge, emphasizing the necessity for ongoing research. A multidisciplinary approach, tailored to individual patient profiles, is crucial for maximizing efficacy while minimizing toxicity. As we strive to optimize breast cancer management, a comprehensive understanding of the distinct characteristics and treatment implications of luminal and triple-negative subtypes, including the transformative role of immunotherapy, is essential for informed decision-making and personalized care.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11416407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141983790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent Advances in Liver Transplantation for Hepatocellular Carcinoma. 肝细胞癌肝移植的最新进展。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-09-01 Epub Date: 2024-08-01 DOI: 10.1007/s11864-024-01247-8

P Jonathan Li, Sachin Shah, Neil Mehta

{"title":"Recent Advances in Liver Transplantation for Hepatocellular Carcinoma.","authors":"P Jonathan Li, Sachin Shah, Neil Mehta","doi":"10.1007/s11864-024-01247-8","DOIUrl":"10.1007/s11864-024-01247-8","url":null,"abstract":"Opinion statement: Liver transplantation for hepatocellular carcinoma (HCC) remains an evolving field. Major challenges HCC transplant patients face today include liver organ donor shortages and the need for both better pre-transplant bridging/downstaging therapies and post-transplant HCC recurrence treatment options. The advent of immunotherapy and the demonstrated efficacy of immune checkpoint inhibitors in multiple solid tumors including advanced/unresectable HCC hold promise in expanding both the neoadjuvant and adjuvant HCC transplant treatment regimen, though caution is needed with these immune modulating agents leading up to and following transplant. New options for pre-transplant HCC management will expand access to this curative option as well as ensure patients have adequate control of their HCC prior to transplant to maximize the utility of a liver donor. Machine perfusion has been an active area of investigation in recent years and could expand the organ donor pool, helping address current liver donor shortages. Finally, additional HCC biomarkers such as AFP-L3 and DCP have shown promise in improving risk stratification of HCC patients. Together, these three recent advancements will likely alter HCC transplant guidelines in the coming years.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11416390/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer. 揭开新辅助疗法的神秘面纱：对 HER2 阳性早期乳腺癌的见解和展望。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-09-01 Epub Date: 2024-08-17 DOI: 10.1007/s11864-024-01252-x

Hervé Bischoff, Marc Espié, Thierry Petit

引用次数: 0

Prediction of Response to FDA-Approved Targeted Therapy and Immunotherapy in Acute Lymphoblastic Leukemia (ALL). 预测急性淋巴细胞白血病 (ALL) 对 FDA 批准的靶向疗法和免疫疗法的反应。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-09-01 Epub Date: 2024-08-05 DOI: 10.1007/s11864-024-01237-w

Zakaria Yahya Khawaji, Nussaiba Yahya Khawaji, Mohammed Abdullah Alahmadi, Abeer Abd Elmoneim

{"title":"Prediction of Response to FDA-Approved Targeted Therapy and Immunotherapy in Acute Lymphoblastic Leukemia (ALL).","authors":"Zakaria Yahya Khawaji, Nussaiba Yahya Khawaji, Mohammed Abdullah Alahmadi, Abeer Abd Elmoneim","doi":"10.1007/s11864-024-01237-w","DOIUrl":"10.1007/s11864-024-01237-w","url":null,"abstract":"Opinion statement: Acute lymphoblastic leukemia (ALL) represents the predominant cancer in pediatric populations, though its occurrence in adults is relatively rare. Pre-treatment risk stratification is crucial for predicting prognosis. Important factors for assessment include patient age, white blood cell (WBC) count at diagnosis, extramedullary involvement, immunophenotype, and cytogenetic aberrations. Minimal residual disease (MRD), primarily assessed by flow cytometry following remission, plays a substantial role in guiding management plans. Over the past decade, significant advancements in ALL outcomes have been witnessed. Conventional chemotherapy has remarkably reduced mortality rates; however, its intensive nature raises safety concerns and has led to the emergence of treatment-resistant cases with recurrence of relapses. Consequently, The U.S. Food and Drug Administration (FDA) has approved several novel treatments for relapsed/refractory ALL due to their demonstrated efficacy, as indicated by improved complete remission and survival rates. These treatments include tyrosine kinase inhibitors (TKIs), the anti-CD19 monoclonal antibody blinatumomab, anti-CD22 inotuzumab ozogamicin, anti-CD20 rituximab, and chimeric antigen receptor (CAR) T-cell therapy. Identifying the variables that influence treatment decisions is a pressing necessity for tailoring therapy based on heterogeneous patient characteristics. Key predictive factors identified in various observational studies and clinical trials include prelymphodepletion disease burden, complex genetic abnormalities, and MRD. Furthermore, the development of serious adverse events following treatment could be anticipated through predictive models, allowing for appropriate prophylactic measures to be considered. The ultimate aim is to incorporate the concept of precision medicine in the field of ALL through valid prediction platform to facilitate the selection of the most suitable treatment approach.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141890758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolution of Treatment Strategies for Gestational Trophoblastic Neoplasia: Chemotherapy, Immunotherapy, and Molecular Targeted Therapy. 妊娠滋养细胞肿瘤治疗策略的演变：化疗、免疫疗法和分子靶向疗法。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-08-01 Epub Date: 2024-07-25 DOI: 10.1007/s11864-024-01235-y

Xiangyu Wang, Jianlei Wu, Wenli Xie

{"title":"Evolution of Treatment Strategies for Gestational Trophoblastic Neoplasia: Chemotherapy, Immunotherapy, and Molecular Targeted Therapy.","authors":"Xiangyu Wang, Jianlei Wu, Wenli Xie","doi":"10.1007/s11864-024-01235-y","DOIUrl":"10.1007/s11864-024-01235-y","url":null,"abstract":"Opinion statement: In addressing Gestational Trophoblastic Neoplasia (GTN), it is imperative to acknowledge the evolving landscape of treatment options, especially in light of the challenges posed by traditional methods. While historically, surgical interventions, radiation therapy, and chemotherapeutic agents have been the mainstays, the emergence of resistance and high-risk scenarios necessitates a reevaluation of our therapeutic approaches. Our review highlights the promising advancements in immunotherapy and molecular targeted therapy as viable alternatives for GTN management. The introduction of immune checkpoint inhibitors and kinase inhibitors offers a paradigm shift, particularly for patients resistant to conventional chemotherapy regimens. These novel therapies not only exhibit efficacy but also demonstrate manageable toxicity profiles, particularly in high-risk cases. However, integrating these innovative treatments into established international guidelines presents a formidable task. As we move forward, it is imperative that future research not only prioritizes fertility preservation but also rigorously evaluates long-term toxicity implications. International collaboration becomes pivotal in addressing the nuances of this rare and complex disease. In conclusion, our review underscores the need for a nuanced approach to GTN treatment, one that prioritizes reduced toxicity and improved quality of life. By embracing the advancements in immunotherapy and molecular targeted therapy, we can pave the way for more effective and patient-centered care in the management of GTN.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients. 治疗成人急性淋巴细胞白血病复发。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-08-01 Epub Date: 2024-06-25 DOI: 10.1007/s11864-024-01213-4

John C Molina, Hetty E Carraway

{"title":"Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients.","authors":"John C Molina, Hetty E Carraway","doi":"10.1007/s11864-024-01213-4","DOIUrl":"10.1007/s11864-024-01213-4","url":null,"abstract":"Opinion statement: For adult patients diagnosed with relapsed B cell-ALL (B-ALL), there have been significant improvements in available treatment options following the FDA approval of novel cellular and immunotherapy approaches - blinatumomab, chimeric antigen receptor (CAR) T therapy, and inotuzumab. For the last several years, research has focused on gaining a better understanding of the effects of specific disease and patient characteristics on long-term outcomes with each of the FDA-approved agents. In combination with the better prevention and management of unique, treatment-specific toxicities, providers can now select the best available treatment option for each individual patient diagnosed with relapsed, adult B-ALL needing therapy. This has allowed more patients to proceed to consolidative hematopoietic stem cell transplant (HSCT), and long-term data has even brought into question the need for HSCT for long-term durable remission for all patients. However, with the adoption of blinatumomab, CAR T therapy, and inotuzumab in front-line treatment regimens, it remains unclear what effects this will have on patients with relapsed B-ALL following exposure to these novel cellular and immunotherapy therapies. Unlike B-ALL, similar advances have unfortunately not yet been realized in T cell-ALL (T-ALL). Currently, new therapeutic approaches are underway to utilize similar targeting strategies that have been successful in B-ALL - monoclonal antibodies, bispecific T-cell engagers (BiTE), and CAR T therapy. Like B-ALL, the only existing approved therapy for relapsed T-ALL, nelarabine, is now used in the upfront treatment setting potentially limiting its utility in relapsed disease. Over the next several years, the hope is for patients diagnosed with T-ALL to experience the drastic improvement in outcomes as has been seen for patients diagnosed with B-ALL over the last decade.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11329612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141447433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0